Clinical Trial

Predictors of Trifecta Achievement After HoLEP

Study acronym: ReMIUS-BPO
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Holmium laser enucleation of the prostate (HoLEP) is a surgical treatment option for men experiencing bothersome lower urinary tract symptoms due to an enlarged prostate. Researchers predict that specific participant or operator-dependent conditions before or during HoLEP may influence the trifecta outcome, based on similar studies. Therefore, the aim of this study is to understand what these conditions are. Trifecta success indicates a high-quality surgery based on three essential criteria: the treatment's effectiveness, ease of recovery, and the absence of serious side effects. In this study, trifecta is defined as relief from bothersome symptoms validated by international symptom score questionnaires, no urinary incontinence, and no serious events occurring within three months after HoLEP.
Trial Details
NCT Number NCT07429994
Lead Sponsor Ondokuz Mayıs University
Conditions HoLEP, Trifecta Achievement, Urinary Incontinence Following Surgical Procedure, Clavien Dindo Surgical Complication Scale, Lower Urinary Tract Symptoms (LUTS), Benign Prostatic Enlargement (BPE), Bladder Outlet Obstruction
Enrollment 604 participants
Start Date 2026-01-30
Primary Completion 2028-04-26 (estimated)
Study Completion 2028-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-24